SGTA Recognizes a Noncanonical Ubiquitin-like Domain in the Bag6-Ubl4A-Trc35 Complex to Promote Endoplasmic Reticulum-Associated Degradation  by Xu, Yue et al.
Cell Reports
ArticleSGTA Recognizes a Noncanonical Ubiquitin-like
Domain in the Bag6-Ubl4A-Trc35 Complex to Promote
Endoplasmic Reticulum-Associated Degradation
Yue Xu,1 Mengli Cai,2 Yingying Yang,3 Lan Huang,3 and Yihong Ye1,*
1Laboratory of Molecular Biology
2Laboratory of Chemical Physics
National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA
3Department of Biophysics and Physiology, University of California Irvine, Irvine, CA 92612, USA
*Correspondence: yihongy@mail.nih.gov
http://dx.doi.org/10.1016/j.celrep.2012.11.010SUMMARY
Elimination of aberrantly folded polypeptides from
the endoplasmic reticulum (ER) by the ER-associ-
ated degradation (ERAD) system promotes cell
survival under stress conditions. This quality control
mechanism requires movement of misfolded
proteins across the ER membrane for targeting to
the cytosolic proteasome, a process facilitated by
a ‘‘holdase’’ complex, consisting of Bag6 and the
cofactors Ubl4A and Trc35. This multiprotein
complex also participates in several other protein
quality control processes. Here, we report SGTA as
a component of the Bag6 system, which cooperates
with Bag6 to channel dislocated ERAD substrates
that are prone to aggregation. Using nuclear
magnetic resonance spectroscopy and biochemical
assays,wedemonstrate that SGTAcontains a nonca-
nonical ubiquitin-like-binding domain that interacts
specifically with an unconventional ubiquitin-like
protein/domain in Ubl4A at least in part via electro-
statics. This interaction helps recruit SGTA to Bag6,
enhances substrate loading to Bag6, and thus
prevents the formation of nondegradable protein
aggregates in ERAD.INTRODUCTION
Ubiquitin-like proteins/domains (UBLs) are a family of structur-
ally related polypeptides, 45–80 amino acids in length. These
proteins share striking structural similarities with ubiquitin (van
der Veen and Ploegh, 2012). Some UBL proteins can be conju-
gated to substrates analogously to ubiquitin (Kerscher et al.,
2006). These ubiquitin-like modifiers are often referred to as
type I UBLs. Other UBLs are present in polypeptides, where
they serve as functional domains. These are termed type II
UBL domains (Jentsch and Pyrowolakis, 2000). In humans, there
are approximately 50 proteins bearing type II UBL domains.
These proteins perform a variety of essential cellular functions,Cell Reserving as proteasome adaptors, ubiquitin ligases (E3), cocha-
perones, deubiquitinating enzymes, and signaling regulators
(van der Veen and Ploegh, 2012; Hoeller et al., 2006). Despite
structural similarities, type I UBL domains often have intrinsic
differences that allow each of them to communicate with
a unique downstream partner. By contrast, the conventional
view on type II UBL domains is that they resemble each other
more than they differ, as many of them can interact with ubiquitin
binding domains (UBDs), such as ubiquitin associated (UBA),
ubiquitin interacting motif, and coupling of ubiquitin to endo-
plasmic reticulum (ER) degradation (CUE) (Hicke et al., 2005;
Husnjak and Dikic, 2012).
An important function of ubiquitin and UBL domains is to regu-
late proteasome-dependent turnover of misfolded proteins of
the ER by the ER-associated degradation system (ERAD) (Tsai
et al., 2002; Vembar and Brodsky, 2008; Meusser et al., 2005).
This evolutionarily conserved protein quality control process
requires a coordinated effort from a large number of proteins,
making up a complex machinery (Smith et al., 2011; Liu and
Ye, 2011). ER chaperones and lectins, such as BiP, Os9,
EDEM, and PDI, recognize misfolded proteins in the lumen and
target them to distinct ubiquitin ligase-containing membrane
complexes for retrotranslocation into the cytosol (Bhamidipati
et al., 2005; Carvalho et al., 2006; Denic et al., 2006;
Oda et al., 2003; Molinari et al., 2003; Kim et al., 2005; Christian-
son et al., 2008; Gauss et al., 2006; Tsai et al., 2001). Substrates
undergoing retrotranslocation are then ubiquitinated by these
ligases (Mehnert et al., 2010) and subsequently dislocated into
the cytosol by the p97-Ufd1-Npl4 ATPase complex for degrada-
tion by the proteasome (Rabinovich et al., 2002; Bays et al.,
2001; Ye et al., 2001; Jarosch et al., 2002).
One of the best characterized ERAD-specific ubiquitin ligases
in mammalian cells is gp78. gp78 is a multispanning transmem-
brane ubiquitin ligase (E3) that is homologous to Hrd1, another
ERAD-dedicated E3 proposed to form a retrotranslocon (Fang
et al., 2001; Carvalho et al., 2010). As amaster retrotranslocation
regulator, gp78 uses a Ube2g2 binding region and a valosin-
containing protein-interacting motif (VIM) domain to interact
with its cognate conjugating enzyme (E2) Ube2g2 and the dislo-
cation-driving p97 ATPase, respectively (Li et al., 2009; Das
et al., 2009; Ye et al., 2005; Ballar et al., 2006; Christianson
et al., 2012). In addition, gp78 also carries a ubiquitin-bindingports 2, 1633–1644, December 27, 2012 ª2012 The Authors 1633
CUEdomain (Chen et al., 2006), which binds aUBL domain in the
recently identified chaperone Bag6. We previously showed that
Bag6 uses an unusual ‘‘holdase’’ activity to maintain retrotrans-
located polypeptides in soluble state, facilitating their turnover
(Wang et al., 2011b).
In this report, we demonstrate that the Bag6 complex contains
an unusual UBL domain in its cofactor Ubl4A, which does not
interact with canonical UBDs. Instead, our biochemical and
structural analyses support the notion that the UBL domain in
Ubl4A represents a unique class of UBL domains. Mass spec-
trometry studies identify an ERAD mediator that specifically
binds the Ubl4A UBL via a mode distinct from the conventional
UBL-UBD interactions. Our data show that distinct means of
UBL recognitions are used in the cell to integrate various
ERAD components into a functional network for protein turnover.
RESULTS
The Bag6 Complex Contains a Canonical and
a Noncanonical UBL Domain
Bag6 contains a UBL domain that binds the CUE domain of
gp78. It is noteworthy that another integral component of the
Bag6 complex, Ubl4A, also contains a UBL domain that shares
significant sequence similarity with the Bag6 UBL, but it is
unclear whether it can interact with CUE. We therefore charac-
terized the interaction of purified Bag6 UBL and Ubl4A UBL
with the gp78 CUE domain (Figure 1A) using solution nuclear
magnetic resonance (NMR) spectroscopy. We first analyzed
chemical shift perturbation of CUE by comparing the chemical
shifts of free CUE (obtained from 15N/13C uniformly labeled
CUE) to that of CUE in complex with Bag6 UBL (15N/13C labeled
CUE plus unlabeled Bag6 UBL). We used ubiquitin as a positive
control, because the CUE domain was previously shown to be
a ubiquitin-binding motif (Chen et al., 2006). The NMR data indi-
cate that the chemical shift perturbation patterns of CUE upon
binding Bag6 UBL and ubiquitin are almost identical (Figures
1B and S1A), suggesting that BAG6 UBL binds the CUE domain
in a similar manner as ubiquitin. We then performed the recip-
rocal experiment by analyzing the chemical shift perturbation
of Bag6 UBL by CUE. We observed three clusters of residues,
containing residues 19–27, 54–66, and 80–86, which display
significant chemical shift perturbation. Among these residues,
Ile60, a residue equivalent to Ile44 of ubiquitin, and His83,
Tyr61, Val65, Val85, and Leu24 (Figures 1C and S1B) form
a hydrophobic patch similar to that in the CUE binding site on
ubiquitin (Kang et al., 2003; Prag et al., 2003). Based on our
NMR results and previously published structures (Protein
Data Bank [PDB] ID code: 1OTR), we built a model of the
Bag6 UBL-CUE complex. As expected, the model is highly
homologous to the CUE-ubiquitin complex (Figure 1D). From
these results, we conclude that Bag6 UBL is a canonical UBL
that is recognized by UBDs in a similar manner as ubiquitin. By
contrast, Ubl4A UBL did not significantly alter the NMR spectra
of CUE (Figures 1B and S1A). We concluded that the Ubl4A UBL
is a distinct type II UBL unrecognizable by UBDs.
To understand why Ubl4A UBL cannot be recognized by CUE,
we compared the protein sequence of Ubl4A UBL to that of
Bag6 UBL. We focused on residues in BAG6 UBL that showed1634 Cell Reports 2, 1633–1644, December 27, 2012 ª2012 The Autsignificant chemical shift perturbation when the CUE domain
was present. Many of these residues are conserved between
Bag6 UBL and Ubl4A UBL, but a few variations were noticed
(Figure 2A). We investigated the contribution of five variations
to the UBD binding specificity by converting these amino acids
in Bag6 UBL to the corresponding ones in Ubl4A UBL either indi-
vidually or in combination. Size exclusion chromatography anal-
yses showed that four Bag6 UBL variants (Y61F, Q62K, Q62A,
and R64K/V65A) bound CUE similarly to wild-type Bag6 UBL
(Y.X., unpublished data). However, a single amino acid substitu-
tion that changed His83 to Asn completely abolished the interac-
tion of Bag6 UBL with CUE (Figures 2B and 2C). This Bag6 UBL
mutant also failed to bind the UBA domain of the gp78-interact-
ing partner UbxD8 (Figures 2D–2F), suggesting that His83 is
required for binding UBDs.
Many type II UBL domains contain histidine or a hydrophobic
amino acid at the position equivalent to His83 of Bag6 UBL, but
others have either a polar or charged residue at this position (Fig-
ure S2A). In either the CUE-ubiquitin or the CUE-Bag6 UBL
complex, the histidine residue is in proximity to several hydro-
phobic residues, but its imidazole ring is oriented away from
the hydrophobic UBD binding pocket (Figure 1D; Kang et al.,
2003; Prag et al., 2003). When this residue is converted to Asn,
computational modeling showed that the polar side chain of
Asn can adopt many rotamers that frequently protrude into the
UBD binding pocket, disrupting the hydrophobic binding site
(Figure S2B). We therefore presumed that the side chain of the
residue equivalent to His83 in Bag6 UBLmight have a significant
impact on whether or not a type II UBL domain could be recog-
nized by a canonical UBD. To test this idea, we mutated His83 in
Bag6 UBL to a variety of residues including alanine (A), the polar
residue threonine (T), hydrophobic residues (L, F, and W), or
charged residues (K and E). Each mutant was purified as a gluta-
thione S-transferase (GST)-tagged protein from E. coli and
tested for binding CUE using a GST pull-down assay. The results
showed that the interaction of Bag6 UBL with CUE was main-
tained when His83 was substituted to a strong hydrophobic
residue, such as F or W. In fact, the H83W substitution consis-
tently increased the affinity of Bag6 UBL to CUE (Figure 2G).
By contrast, substitution of His83 to either charged, polar, or
even less hydrophobic residues, such as leucine, reduced the
interaction of Bag6 UBL with CUE. Thus, a His or strong hydro-
phobic residue is required at this position for Bag6 UBL to be
recognized by a UBD.
To further corroborate our model, we tested two other type II
UBLs that have a charged residue at the position equivalent to
His83. Indeed, neither GST-ZFAN4 UBL nor GST-FUBI bound
CUE, whereas GST-ubiquitin or GST-Bag6 UBL could pull down
CUE under the same condition (Figures S2C and S2D). Together,
our results suggest the existence of a class of type II UBLs that do
not bind canonical UBDs. These UBLs contain unique features,
including a charged or polar residue near the UBD binding site,
which distinguish them from canonical UBLs that bind UBDs.
Ubl4A Binds SGTA through a Noncanonical Mode of UBL
Recognition
We next wished to identify the functional partner(s) of Ubl4A UBL
in the context of ERAD. To this end, we expressed FLAG-taggedhors
Figure 1. Recognition of Bag6 UBL by the CUE Domain
(A) Purified proteins used in the NMR studies.
(B) NMR chemical shift perturbation analyses show that Bag6 UBL binds the gp78 CUE domain in a similar manner as ubiquitin, whereas Ubl4A UBL only interacts
with CUEweakly. The NMR spectra of 15N/13C labeled CUE (400 mM)were determined in the presence or absence of the indicated proteins (800 mM). Shown is the
square root summary of the chemical shift differences (DHz) in both nitrogen and proton dimensions as a function of protein sequence.
(C) The chemical shift perturbations of Bag6 UBL by CUE. As in (B), except that the Bag6 UBL is labeled, whereas CUE is unlabeled.
(D) A structural model of the Bag6 UBL-CUE complex. The model was obtained by aligning the Bag6 UBL structure (PDB: 1WX9, RIKEN Structural Genomics/
Proteomics Initiative) to ubiquitin in the previously determined ubiquitin-CUE complex structure (PDB: 1OTR) (Kang et al., 2003). The enlarged images highlight
the residues involved in CUE binding in Bag6 UBL and ubiquitin.
See also Figure S1.
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Figure 2. His83 in BAG6 UBL Is Required for UBD Binding
(A) Sequence alignment of Bag6 UBL, Ubl4A UBL, and ubiquitin (Ub). Arrowheads indicate nonconserved BAG6 UBL residues, whose 1H/15N chemical shifts are
significantly affected by CUE binding.
(B and C) Size exclusion chromatography analyses of the interactions of Bag6 UBL and Bag6 UBL H83N with gp78 CUE. gp78 CUE (40 mM) was mixed with
Bag6 UBL as indicated and incubated on ice for 30 min before analysis by a size exclusion chromatography at 4C.
(D and E) As in (B) and (C), except that the UBA domain from UbxD8 (40 mM) was used.
(F) The peak fractions in (D) and (E) were analyzed by SDS-PAGE electrophoresis and Coomassie blue staining.
(G) Histidine and strong hydrophobic residues at position 83 of Bag6 UBL support CUE binding. Shown is a GST pull-down experiment using the indicated
proteins.
See also Figure S2.Ubl4A together with His-tagged Bag6 in HEK293 cells, because
the association of Ubl4A with the membrane is mediated by
Bag6 binding to gp78. We purified the Ubl4A-Bag6 complex
from both an ER-enriched membrane fraction and a cytosolic
fraction by affinity chromatography. Eluted proteins were
analyzed by mass spectrometry using a shotgun approach.
Among proteins identified as potential Ubl4A-Bag6 interacting
proteins, a protein named SGTA was chosen for further investi-
gation, because of its abundance in the eluate and because
the interaction with the Bag6-Ubl4A complex was detected in
both the cytosol and membrane fractions (Table S1). In addition,
the yeast SGTA homolog Sgt2p was reported to interact with
Get5p, an ortholog of Ubl4A (Chartron et al., 2011; Wang et al.,
2010; Chang et al., 2010; Kohl et al., 2011).1636 Cell Reports 2, 1633–1644, December 27, 2012 ª2012 The AutTo validate the mass spectrometric results, we carried
out coimmunoprecipitation and immunoblotting experiments.
When FLAG-tagged Ubl4A was expressed either by itself or
together with His-tagged Bag6, immunoprecipitation of Ubl4A
pulled down endogenous SGTA. By contrast, overexpressed
Bag6 alone did not coprecipitate with SGTA efficiently (Fig-
ure 3A). Endogenous SGTA could also be coprecipitated with
the endogenous Bag6 complex (Figure 3B). These results
suggest that SGTA interacts with the Bag6 complex in cells likely
through Ubl4A.
We next determined the region in SGTA that is responsible for
Ubl4A binding. We created constructs expressing various SGTA
fragments. Immunoprecipitation showed that the N-terminal 80
amino acids of SGTA (SGTA-N) were both necessary andhors
Figure 3. SGTA Binds Ubl4A UBL via Elec-
trostatics
(A) Ubl4A interacts with SGTA. Cells expressing
the indicated proteins were analyzed by immu-
noprecipitation and immunoblotting.
(B) Endogenous interaction between SGTA and
the Bag6 complex. HEK293 cell extract was
subject to immunoprecipitation by the indicated
antibodies.
(C) SGTA interacts directly with the UBL domain of
Ubl4A. Shown is a GST pull-down experiment
using the indicated proteins.
(D) SGTA binds Ubl4A UBL by a means that is
distinct from the canonical mode of UBL recog-
nition. Panels 1 and 2 show the electrostatic
surface potential of the surface around the UBD
binding hydrophobic residues (red circles) of
BAG6 UBL and the corresponding ones on Ubl4A
UBL. Panels 3 and 4 are surface views of Ubl4A
UBL and Bag6 UBL, respectively, showing resi-
dues whose NMR spectra are significantly
affected by their corresponding partner (green for
Ubl4A UBL and pink for Bag6 UBL).
(E) The interaction of Ubl4A UBL with SGTA is
sensitive to salt. The indicated GST-tagged
proteins were immobilized and incubated with
SGTA-N either under low (L, 150 mM) or high salt
conditions (H, 500 mM). The precipitated proteins
were analyzed by SDS-PAGE andCoomassie blue
staining.
See also Figure S3 and Table S1.sufficient for Ubl4A binding (Figures S3A and S3B), consistent
with studies in yeast (Chartron et al., 2011, 2012).
To see whether the UBL domain in Ubl4A is involved in SGTA
binding, we incubated GST or GST-tagged Ubl4A UBL with
a whole cell extract. Indeed, immunoblotting showed that
GST-Ubl4A UBL, but not GST, interacted with endogenous
SGTA (Figure S3C). In addition, GST-Ubl4A UBL could also
pull down a purified recombinant SGTA-N, demonstrating
a direct interaction between these proteins (Figure 3C).Cell Reports 2, 1633–1644, DeCompared to GST-Ubl4A UBL, GST-
Bag6 UBL pulled down less SGTA-N,
whereas GST-ubiquitin, GST-FUBI, and
GST-ZFAN4 UBL did not pull down
SGTA-N above the background level
(Figures 3C and S3D). Thus, SGTA is
a UBL-binding protein that preferentially
interacts with Ubl4A UBL.
To further characterize the interaction
between SGTA-N and Ubl4A UBL, we
uniformly labeled Ubl4A UBL with
15N/13C and obtained backbone 1H/15N
chemical shift assignments of Ubl4A
UBL in complex with SGTA-N. The chem-
ical shift perturbation profile for Ubl4A
UBL upon binding of SGTA was com-
pared to the CUE-induced chemical shift
perturbation of Bag6 UBL. The overall
chemical shift perturbation patterns ap-peared similar, but a careful comparison of the two profiles
showed that some Ubl4A UBL residues perturbed by SGTA
were not significantly affected by CUE in Bag6 UBL and vice
versa (Figures S3E and S3F). These results indicate that Ubl4A
UBL employs a site similar to the UBD binding site on canonical
UBL domains for binding SGTA, but the precise mode of interac-
tions may be different. Indeed, the electrostatic surface potential
of the SGTA binding site in Ubl4A UBL is significantly different
from that of the canonical UBD binding surface on Bag6 UBLcember 27, 2012 ª2012 The Authors 1637
Figure 4. Ubl4A Helps Recruit SGTA to
Bag6
(A) A model of the Ubl4A UBL-SGTA N-domain
complex. The structures of Ubl4A UBL (PDB:
2DZI, RIKEN Structural Genomics/Proteomics
Initiative) and SGTA-N (PDB: 4GOD) were aligned
to the corresponding domain in the homologous
yeast Get5p UBL-Sgt2p N complex (PDB: 2LXC).
(B) Two acidic residues on SGTA-N are essential
for interaction with Ubl4A and Bag6. HEK293 cells
transfected with plasmids expressing the indi-
cated FLAG-tagged proteins were lysed in the
NP40 lysis buffer. Cell extracts were subject to
immunoprecipitation with the FLAG antibody, and
the precipitated materials were analyzed by
immunoblotting.
(C) Purified proteins for in vitro binding studies. A
known amount of BSA was used to estimate
protein concentrations. The numbers indicate the
protein levels.
(D) Ubl4A promotes SGTA binding Bag6 in vitro.
Purified SGTA or the D27R/E30R mutant was
incubated with either Bag6 or the Bag6-Ubl4A
complex (Bag6-Ubl4A). After incubation, the
samples were subject to immunoprecipitation and
immunoblotting analyses. The numbers indicate
the amount of Bag6 coprecipitated with SGTA.
(E) Ubl4A promotes the interaction of SGTA with
Bag6 in cells. HEK293 cells expressing the indi-
cated proteins were lysed. The cell extracts were
subject to immunoprecipitation by FLAG anti-
bodies.(Figure 3D). In Bag6 UBL, the imidazole ring of His83 is pointed
away from Leu24, Ile60, and Val85, allowing the latter to form
a continuous hydrophobic binding surface. By contrast, Asn68
in Ubl4A UBL disrupts this hydrophobic surface. Importantly,
Leu44 and Val70 in Ubl4A UBL (equivalent to Ile60 and Val80
in Bag6 UBL, respectively) are surrounded by positively charged
residues (Figure 3D, panel 1), and 1H/15N chemical shift
perturbation shows that many of these charged residues were
significantly perturbed upon binding SGTA (panel 3). Thus, elec-1638 Cell Reports 2, 1633–1644, December 27, 2012 ª2012 The Authorstrostatic side chain contacts may
contribute significantly to the Ubl4A
UBL-SGTA interaction. In support of this
notion, we found that the interaction of
SGTA with Ubl4A was highly sensitive to
salt treatment (Figure 3E). Together these
results demonstrate a means of UBL
recognition that is mediated at least in
part by electrostatics, a conclusion that
is in accordance with a study in yeast
(Chartron et al., 2012).
Ubl4A Enhances the Association of
SGTA with Bag6
To test whether Ubl4A helps recruit SGTA
to Bag6, we took two approaches. First,
we generated a structural model of the
human SGTA N-domain in complex withUbl4A UBL by aligning the SGTA-N and Ubl4A UBL structures
with the yeast homologous complex (Chartron et al., 2012).
The model indicates that the side chains of two highly conserved
acidic residues in SGTA (Asp27 and Glu30) make contacts with
Lys48 and Lys6 in Ubl4A, respectively, two residues showing
significant chemical shift perturbation in our NMR study (Fig-
ure 4A). We expressed either wild-type SGTA or a SGTA mutant
bearing D27R and E30R substitutions in cells. Immunoprecipita-
tion showed that, compared to wild-type SGTA, the D27R/E30R
mutant was completely inactive in binding Ubl4A, but its interac-
tion with Hsc70 was maintained (Figure 4B). The results suggest
that the mutations specifically affect the binding site for Ubl4A.
Consistent with the notion that Ubl4A serves a link between
SGTA and Bag6, Bag6 was not coprecipitated with the SGTA
mutant defective in Ubl4A binding. Next, we reconstituted the
Ubl4A-dependent interaction of SGTA with Bag6 in vitro using
purified SGTA and Bag6 or a Bag6-Ubl4A complex. We purified
these proteins fromHEK293 cells under a high salt condition (see
Experimental Procedures). Nonetheless, the Bag6 sample con-
tained some endogenous Ubl4A. As expected, when Ubl4A
was coexpressed with Bag6, the purified complex contained
Bag6 and Ubl4A in stoichiometric ratio (Figure 4C). Coimmuno-
precipitation experiments demonstrate that purified Bag6 only
moderately coprecipitated SGTA (Figure 4D, lane 8). This asso-
ciation is probably mediated by the weak affinity between the
Bag6 UBL and SGTA N-domain (Winnefeld et al., 2006). The
small amount of endogenous Ubl4A present in the sample may
also contribute to this interaction. Importantly, the interaction
of Bag6 with SGTA, but not SGTA D27R/E30R, was significantly
enhanced when a stoichiometric amount of Ubl4A was present
(lane 10 versus lanes 8 and 12). Likewise, ectopically expressed
Bag6 did not interact significantly with endogenous SGTA in
cells (Figures 3A and 4E, lane 4), but coexpression of Ubl4A
enhanced the interaction (Figure 4E, lane 3 versus lane 4). We
conclude from these experiments that Ubl4A can serve as
a matchmaker to enhance SGTA binding to Bag6.
Depletion of SGTA Impairs ERAD and Induces Unfolded
Protein Response
The Bag6 complex was recently established as a key regulator in
membrane targeting of tail-anchored (TA) proteins (Mariappan
et al., 2010). Importantly, the same complex also plays pivotal
roles in several aspects of protein quality control (Wang et al.,
2011b; Hessa et al., 2011; Minami et al., 2010). Notably, yeast
does not contain a Bag6 homolog, but it contains a SGTA ortho-
log named Sgt2p, which binds Get5p, the ortholog of Ubl4A. In
yeast, Sgt2p appears to serve as a functional ‘‘substituent’’ for
Bag6 in TA protein biogenesis, but it is unclear whether Sgt2p
or SGTA has the capacity to regulate any proteasomal degrada-
tion processes.
We therefore tested whether SGTA can function in ERAD. We
first used two different SGTA specific small hairpin RNAs
(shRNAs) to deplete SGTA in a cell line stably expressing the
model ERAD substrate T cell receptor (TCR)a-yellow fluorescent
protein (YFP), because the degradation of this substrate requires
both gp78 and the Bag6 complex (Wang et al., 2011b). Immuno-
blotting showed that depletion of SGTA by >80% increased the
steady state level of TCRa-YFP by at least 5-fold (Figure 5A).
Cycloheximide chase experiments showed that the turnover of
TCRa-YFP was significantly inhibited by SGTA depletion,
demonstrating that SGTA is functionally required for the turnover
of this ERAD substrate (Figure 5B). SGTA depletion also consis-
tently caused accumulation of another Bag6-dependent ERAD
substrate CD4 in Vpu-expressing cells (Figure S4). Intriguingly,
fluorescence microscopy revealed that, in SGTA knockdown
cells, TCRa-YFP often accumulated in aggresome-like struc-
tures (Figure 5C), a phenotype similarly observed in Bag6-Cell Redepleted cells (Wang et al., 2011b). Consistently, a significant
fraction of TCRa-YFP in SGTA knockdown cells could not be
extracted by the nonionic detergent NP40, due to aggregation
(Figure 5D). Collectively, these results suggest that SGTA may
cooperate with Bag6 to maintain the solubility of retrotranslo-
cated ERAD substrates and therefore promote their turnover.
To test whether SGTA has a broad role in ERAD, we asked
whether depletion of SGTA elicits the unfolded protein response
(UPR), a stress response inducedwhenmisfolded proteins accu-
mulate in the ER. If SGTA is a general regulator of ERAD, its defi-
ciency should cause accumulation of misfolded ER proteins and
induce ER stress. We first used an enhanced green fluorescent
protein (EGFP)-tagged XBP1 (XBP1 DDBD Venus) as a reporter
(Iwawaki et al., 2004). The splicing of XBP1 uponER stress induc-
tion (e.g., in cells depleted of p97 or tunicamycin-treated cells)
activates the expression of EGFP, which was also detected in
cells depleted of SGTA (Figure 5E). UPR induction in SGTA
knockdown cells could also be verified using a BiP promoter-
controlled luciferase reporter [GRP78 (132)-Luc] (Figure 5F;
Yoshida et al., 2001). These results are consistent with the
proposed function of SGTA in ERAD regulation. However, the
data cannot rule out the possibility that SGTA may also use
anothermechanism independent of ERAD to regulateERhomeo-
stasis, because UPR induction was similarly observed in yeast
strain deficient in Sgt2 (Jonikas et al., 2009), yet no evidence
suggests thatSgt2phas a role in ERAD regulation inS. cerevisiae.
SGTA Promotes Substrate Binding by Bag6 to Facilitate
ERAD
Bag6 has a chaperone-like activity that binds proteins bearing
exposed hydrophobic surfaces to inhibit their aggregation
(Wang et al., 2011b; Mariappan et al., 2010). To capture retro-
translocated ERAD substrates in cells, Bag6 needs to compete
with many abundant cytosolic chaperones that have similar
activities. We hypothesized that SGTA may be a substrate re-
cruiting cofactor that improves the efficiency of substrate binding
by Bag6 in the complex cellular environment. We therefore
tested whether SGTA itself could bind proteins with exposed
hydrophobic patches. We used luciferase as a model substrate,
because it could be readily denatured by heat, exposing a stretch
of hydrophobic residues. As shown previously, purified Bag6 can
capture heat-denatured luciferase and keep it in an unfolded yet
soluble form (Wang et al., 2011b). Under the same condition,
purified SGTA was significantly less effective than Bag6 in sup-
pressing luciferase aggregation, as demonstrated by both light
scattering and sedimentation assays (Figures 6A and S5A).
Nonetheless, an interaction between SGTA and the denatured
luciferase, but not native luciferase, could be detected by coim-
munoprecipitation (Figure 6B). Importantly, luciferase binding is
not dependent on the association of SGTA with Hsc70, because
mutations in the predicted Hsc70 binding site abolished Hsc70
binding (data not shown), but did not affect SGTAbinding to lucif-
erase (Figure S5B). These results indicate that SGTA has a chap-
erone-like activity distinct from that of Bag6: while Bag6 can bind
and hold its substrates, SGTA might bind substrates in a more
transient and dynamic fashion.
Our in vitro experiments so far support the notion that SGTA
may act as a cofactor to enhance substrate binding by Bag6.ports 2, 1633–1644, December 27, 2012 ª2012 The Authors 1639
Figure 5. SGTA Is Required for Degradation
of Misfolded ER Proteins
(A) Depletion of SGTA causes accumulation of the
model ERAD substrate TCRa. Whole cell extracts
from TCRa-YFP-expressing cells transfected with
the indicated shRNA constructs were analyzed by
immunoblotting.
(B) Cycloheximide chase analysis of TCRa turn-
over in control and SGTA knockdown cells.
Because the level of TCRa in control cells is too
low to allow an accurate estimation of the degra-
dation kinetics, we also performed immunopre-
cipitation and quantitative immunoblotting using
cell extracts from the SGTA knockdown and
control cells (bottom panel).
(C) Cells expressing TCRa-YFP together with the
indicated shRNA constructs were imaged by
a fluorescence microscope. Two examples of
SGTA knockdown cells bearing TCRa aggregates
of different sizes are shown. The numbers indicate
the exposure time in milliseconds.
(D) TCRa accumulates in SGTA knockdown cells
in NP40 insoluble fractions. Cells transfected with
a TCRa-YFP-expressing plasmid together with the
indicated shRNAswere extracted first by theNP40
lysis buffer to obtain soluble extracts (S). TheNP40
insoluble fractions (P) were subject to further
extraction by the SDS-containing Laemmli buffer
prior to immunoblotting.
(E and F) SGTA depletion induces ER stress. (E)
Cells transfected with the indicated knockdown
constructs together with the XBP1-Venus reporter
were lysed. Whole cell extracts were analyzed by
immunoblotting. Where indicated, cells were
treated with tunicamycin (Tm) for 9 h. (F) HEK293
cells were transfected with the indicated knock-
down (KD) constructs together with the glucose-
regulated protein -luciferase reporter. A fraction of
the cell extracts were subject to immunoblotting.
The remaining samples were used to determine
the luciferase activities. Shown is the quantifica-
tion of three independent experiments (error bars,
standard deviation, n = 3).
See also Figure S4.This would explain the substrate aggregation phenotype
observed in cells lacking either SGTA or Bag6. We previously
showed that a Bag6-containing complex carrying dislocated
TCRa could be detected by immunoprecipitation upon inhibition
of the proteasome. Using this assay, we found that depletion of
SGTA by expressing a SGTA-specific shRNA reproducibly
reduced the level of Bag6-associated TCRa, even though the
total level of TCRa was significantly increased by SGTA knock-1640 Cell Reports 2, 1633–1644, December 27, 2012 ª2012 The Authorsdown (Figure 6C). We concluded that
SGTA may assist Bag6 in capturing
retrotranslocated ERAD substrates, pro-
moting their turnover.
DISCUSSION
Many type II UBL domains in cells can
be recognized by UBDs in a mannersimilar to ubiquitin (van der Veen and Ploegh, 2012; Mueller
and Feigon, 2003). Consistent with this notion, we establish
the UBL domain in Bag6 as a canonical type II UBL that is
recognized by UBDs in a similar mode to ubiquitin. However,
our study also reveals the existence of a class of type II UBL
that cannot be recognized by UBDs. We propose to refer to
the canonical UBLs as type IIa UBLs and the nonconventional
ones as type IIb UBLs. A representative of the type IIb class is
Figure 6. SGTA Assists Bag6 in Chaperoning ERAD Substrates
(A) SGTAweakly suppresses luciferase aggregation in vitro. Light scattering analysis of luciferase aggregation in the presence of the purified proteins at 42C. The
molar ratio of luciferase to the chaperones or BSA is 1:3.
(B) SGTA preferentially binds unfolded luciferase. SGTA was incubated with luciferase at 42C or 4C for 10 min. The soluble fractions were subject to immu-
noprecipitation with FLAG or control agarose beads. The asterisk indicates immunoglobulin G.
(C) SGTA facilitates substrate binding by Bag6. TCRa-YFP-expressing cells transfected with the indicated shRNA constructs were treated with MG132 for the
indicated periods of time. The interaction of Bag6 with TCRa was analyzed by coimmunoprecipitation.
(D) Amodel shows the roles of the twoUBL domains of the Bag6 complex in ERAD. The red arrows indicate the proposed routes for targeting the ERAD substrates
to the proteasome.
See also Figure S5.found in Ubl4A, which does not bind either CUE or UBA
domains.
We identify SGTA as a functional partner of Ubl4A UBL. As ex-
pected, SGTA does not contain any previously known UBDs,
and the interaction of SGTA with Ubl4A UBL does not resemble
UBD binding to ubiquitin. Instead, SGTA utilizes its N-terminal
domain to form a dimer, which uses symmetric electrostaticsCell Reto interact with the Ubl4A UBL, a feature that is conserved in
the yeast system (Chartron et al., 2012). Notably, Ubl4A has an
unusually high pI of 8.7, whereas the pI of SGTA is 4.7, suggest-
ing that these proteins carry opposite charges at the physiolog-
ical pH. This provides a plausible explanation for the observed
electrostatic interactions. Interestingly, notwithstanding the
distinct UBL recognition mechanisms, SGTA binds Ubl4A UBLports 2, 1633–1644, December 27, 2012 ª2012 The Authors 1641
to a site overlapping with the UBD binding surface on canonical
UBLs. Thus, evolution seems to have re-engineered the UBD
binding surface on Ubl4A UBL to accommodate a unique func-
tional partner. This theme may be reiterated by other type IIb
UBL domains. In this regard, it would be interesting to identify
the functional partners of other type IIb UBL domains in the cell.
We showed previously that the Bag6 complex interacts with
gp78, a key component of a multisubunit complex required for
degradation of many misfolded ER proteins by ERAD. Intrigu-
ingly, many proteins in the gp78 pathway have either a type II
UBL domain or a UBD. Specifically, gp78 itself has a CUE
domain and two of its interactors, UbxD8 and UBAC2, each
contain a UBA domain (Christianson et al., 2012). The p97
complex also contains several ubiquitin-binding domains (Ye
et al., 2003). Proteins bearing a UBL domain in the gp78 complex
include HERP and TMUB1 (Okuda-Shimizu and Hendershot,
2007; Jo et al., 2011). In addition, the Bag6 complex contains
two UBL domains: one in Bag6 and the other in Ubl4A (Wang
et al., 2011b). It was originally thought that the ERAD machin-
eries might use UBDs to capture misfolded proteins undergoing
retrotranslocation and ubiquitination. However, the frequent
presence of UBL domains in the ERAD machineries suggests
an alternative model in which the UBDs in the ERAD network
may use these UBLs as ‘‘connecting bolts’’ to facilitate
protein-protein interactions between distinct ERAD subcom-
plexes. Indeed, we demonstrate that the two UBL domains in
the Bag6 complex can serve an adaptor function that links this
‘‘holdase’’ to different ERAD machineries. The UBL domain in
Bag6 binds the CUE domain in the gp78 ligase complex,
whereas the Ubl4A uses a noncanonical UBL to recruit SGTA.
These observations establish a UBL-dependent protein network
essential for ER protein quality control (Figure 6D).
The Bag6-Ubl4A-Trc35 complex can function as a chaperone
holdase to channel retrotranslocated ERAD substrates to the
proteasome for degradation while maintaining their solubility
(Wang et al., 2011b). Intriguingly, this holdase activity can be
used for chaperoning newly synthesized TA proteins to the ER
membrane or for degradation of mislocalized membrane
proteins (Mariappan et al., 2010; Leznicki et al., 2010; Hessa
et al., 2011). Our studies implicate SGTA as another critical
component of the Bag6 system in ERAD. Given the broad partic-
ipation of Bag6 in various protein quality control processes,
SGTA may also function in other protein degradation pathways.
SGTA is homologous to Sgt2p in yeast. It was shown previously
that Get5p, the ortholog of Ubl4A, can interact and function with
Sgt2p as well as a downstream ATPase named Get3p, resulting
in the handoff of TA proteins from Sgt2p to Get3p (Wang et al.,
2010, 2011a; Chartron et al., 2011; Chang et al., 2010). Our
results suggest that, in mammalian cells, Ubl4A may promote
the interaction of SGTA with Bag6 to form a similar chaperone
axis that facilitates substrate transfer from SGTA to Bag6
(Figure 6D). We propose that SGTA may serve as the initial
‘‘interrogator’’ when misfolded substrates are emerging from
an ER retrotranslocon. SGTA may identify aggregation-prone
substrates and transfer them to Bag6 for further shielding until
degradation occurs. It is also possible that SGTA may function
with other downstream chaperones/effectors to promote
substrate targeting to the proteasome. These chaperoning1642 Cell Reports 2, 1633–1644, December 27, 2012 ª2012 The Autcascades would effectively protect cells against protein aggre-
gation by ensuring that all aberrantly folded ER proteins are effi-
ciently ‘‘shepherded’’ to the proteasome for degradation.
EXPERIMENTAL PROCEDURES
Immunoblotting, Immunoprecipitation, and Pull-down
Cells were lysed in the NP40 lysis buffer containing 50 mM Tris-HCl pH 7.4,
150 mM sodium chloride, 2 mM magnesium chloride, 0.5% NP40, and
a protease inhibitor cocktail. Cell extracts were subject to centrifugation to
remove insoluble materials. For most experiments, the supernatant fractions
were analyzed.Where indicated in the figure legends, the NP40 insoluble pellet
fractions were resolubilized by the Laemmli buffer for immunoblotting.
Immunoblotting was performed according to the standard protocol. Fluores-
cence-labeled secondary antibodies (Rockland) were used for detection.
The fluorescent bands were imaged and quantified on a LI-COR Odyssey
infrared imager using the software provided by themanufacturer. For immuno-
precipitation, the whole cell extract was incubated with FLAG-agarose beads
(Sigma) or protein A-Sepharose CL-4B (GE Healthcare) bound with antibodies
against specific proteins. After incubating, the beads were washed two times
by NP40 wash buffer containing 50mM Tris-HCl pH 7.4, 150mM sodium chlo-
ride, 2 mMmagnesium chloride, and 0.1% NP40. The proteins on beads were
assayed by immunoblotting.
For in vitro pull-down, the GST beads-boundGST-tagged bait proteins were
incubated with prey protein, and the pulled down materials were analyzed by
SDS-PAGE. To assay the effect of salt concentration on Ubl4A UBL-SGTA-N
interaction, GST-Ubl4A UBLwas bound toGST beads incubatedwith SGTA-N
in PBS or PBS plus salt (400 mM potassium acetate). The beads were washed
once with the corresponding binding buffer and assayed by SDS-PAGE.
Analytical Size Exclusion Chromatography
Size exclusion chromatography was performed as follows. To study UBL-UBD
interactions, protein or proteins mixtures at the indicated concentration were
incubated on ice for 3 min and then loaded onto a Superdex75 10/300 GL
size exclusion column (GE Healthcare) pre-equilibrated with a buffer con-
taining 20 mM Tris-HCl pH 7.5 and 10 mM 2-ME). The protein(s) was resolved
at a flow rate of 0.5 ml/min on an AKTA (GE Healthcare) automated liquid
chromatography system and assayed by SDS-PAGE. To analyze purified
Bag6, the protein was applied on a Superdex 200 10/300 GL size exclusion
column (GE Healthcare) pre-equilibrated with PBS and resolved at a flow
rate of 0.4 ml/min on an AKTA (GE Healthcare) automated liquid chromatog-
raphy system. To analyze endogenous Bag6, 293T cells were collected from
an 80% confluent 15 cm dish and lysed in 600 ml NP40 lysis buffer containing
a protease inhibitor cocktail. The whole cell extract was filtered through
a 0.22 mm filter and applied onto a Superose 6 10/300 GL size exclusion
column (GE Healthcare) pre-equilibrated with the PB buffer. Fractions of
0.4 ml were collected and analyzed by immunoblotting.
NMR 1H/15N Chemical Shift Perturbation Experiments
All NMR spectra were collected on 0.4 mM protein 15N/13C uniformly labeled
proteins or 0.4 mM 15N/13C-labeled protein mixed with 0.8 mM unlabeled
protein dissolved in 25 mM sodium phosphate at pH 7.4. Sequence-specific
backbone assignments for labeled free proteins and protein/protein com-
plexes were obtained through heteronuclear single quantum coherence (Grze-
siek and Bax, 1992), CBCA(CO)NH, and HNCACB (Clore and Gronenborn,
1991) experiments, recorded at either 25C for analysis of the Bag6 UBL-
CUE interaction or 40C for Ubl4A UBL-SGTA interaction on Bruker DRX600
or DRX500 equipped with Z-gradient and cryoprobe. Spectra were processed
using the program NMRPipe (Delaglio et al., 1995) and analyzed using the
program PIPP (Garrett et al., 2011). The chemical shift perturbation was
determined according to DHz = [(DHz
15N)2 + (DHz
1H)2]1/2 (DHz
1H and DHz
15N
are the observed chemical shift changes in Hz for 1H and 15N, respectively).
Gene Knockdown and Various ERAD Assays
To knock down UbxD8 and SGTA, 0.5 3 106 293T cells were seeded on Day
0 and transfected with shRNA constructs using Lipofectamine 2000 on day 1hors
and day 2. Seventy-two hours after the first transfection, cells were harvested
for various assays. For cycloheximide chase experiments, 3.03 106 cells were
harvested and incubated in 1.8 ml Dulbecco’s modified Eagle’s medium con-
taining 50 mg/ml cycloheximide. Cells were then incubated at 37C for different
time periods. At each time point, 1 3 106 cells were collected. Cell extracts
were prepared in the NP40 lysis buffer. TCRa-YFPwas either analyzed directly
by immunoblotting or was first immunoprecipitated using a green fluorescent
protein (GFP) antibody followed by immunoblotting. To analyze the in vivo
aggregation of ERAD substrates, cells transfected with the TCRa-YFP-
expressing plasmid together with SGTA shRNA knockdown construct were
first solubilized in the NP40 lysis buffer. The detergent insoluble fractions
were further solubilized by the Laemmli buffer.
Luciferase Aggregation and Refolding Assay
Toassay luciferase aggregation, luciferase (80 nM)was incubatedwith the indi-
cated amount of BSA, Bag6, or SGTA at 42C. The scattered light at 330 nm
was measured by Amico-Bowman Series 2 Spectrofluorometer. Luciferase
incubated in the absence of chaperones or in the presence of BSA was as-
sayed as controls. For the luciferase refolding assay, luciferase (500 nM) alone
orwith Bag6 (1mM), or SGTA(1mM)was heat inactivated (42C, 20min) in buffer
A (20mM4-[2-hydroxyethyl]-1-piperazineethanesulfonic acid [HEPES] pH 7.3,
5 mM magnesium acetate, 50 mM potassium chloride, 1 mM dithiothreitol
[DTT]). The total volumewas 28 ml. Themixture was then divided into two equal
portions. One portion was further incubated with 6 ml buffer B (buffer A plus
5 mM ATP), whereas the other portion was incubated with buffer C (buffer
B plus a chaperone mixture containing 2 mM HSP70, 2.4 mM HOP, and
3.3 mM Hdj). The mixtures were incubated at 25C for 30 min. The luciferase
activity was assayed using the LuciferaseReporter GeneAssay-high sensitivity
kit (Roche) according to the protocol provided by the manufacturer.
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